Genprex CFO to cover CEO during treatment; first patient dosed in Phase 2a expansion of Reqorsa

Genprex, Inc.

Catherine Vaczy, EVP and General Counsel, resigned effective Feb 4; company and Vaczy in discussions.
CEO Rodney Varner undergoing treatment for cutaneous lymphoma; Board designates CFO Ryan Confer to act when CEO unavailable.
First patient dosed Jan 2024 in Phase 2a expansion of Acclaim-1 study (Reqorsa + Tagrisso for NSCLC).
Expects to complete Phase 2a enrollment (19 per cohort) by end of 2024; interim analysis in 2025.
Phase 1 data showed no dose-limiting toxicities and extended progression-free survival in some patients.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Ryan Confer

Chief Financial Officer

GNPX · Genprex, Inc.

Filed: February 5, 2024, 6:59 PM ET

the Board has determined that Mr. Confer can and shall act alone in covering when Mr. Varner is unavailable.

Departed

Catherine Vaczy

Executive Vice President, General Counsel and Chief Strategy Officer

GNPX · Genprex, Inc.

Effective: 2024-02-04
Filed: February 5, 2024, 6:59 PM ET

Catherine Vaczy, the Executive Vice President, General Counsel and Chief Strategy Officer of Genprex, Inc. (“Genprex” or the “Company”) notified the Company of her intention to resign. On February 4, 2024, Ms. Vaczy’s employment with the Company was terminated.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ryan Confer changed role as Chief Financial Officer at Genprex, Inc..

Action: designated
Role: Chief Financial Officer

Exact text from the filing

the Board has determined that Mr. Confer can and shall act alone in covering when Mr. Varner is unavailable.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Catherine Vaczy resigned as Executive Vice President, General Counsel and Chief Strategy Officer at Genprex, Inc..

Action: resigned
Role: Executive Vice President, General Counsel and Chief Strategy Officer

Exact text from the filing

Catherine Vaczy, the Executive Vice President, General Counsel and Chief Strategy Officer of Genprex, Inc. (“Genprex” or the “Company”) notified the Company of her intention to resign. On February 4, 2024, Ms. Vaczy’s employment with the Company was terminated.

View on SEC.gov

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-003055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.